Search Result

Results for "

cock+tail

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Arenavirus (1) RABV (1)
By Research Areas:	Infection (2)

Inhibitors & Agonists

Screening Libraries

MCE Kits

Inhibitory Antibodies

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P99811

Rafivirumab CR57	RABV	Infection
Rafivirumab (CR57) is an anti-rabies virus monoclonal antibody for the prophylaxis of rabies. Rafivirumab has neutralizing potency against a broad spectrum of RABV variants. Rafivirumab can be used for research of cocktails .

HY-P992155

Arevirumab Arevirumab-3	Arenavirus	Infection
Arevirumab (Arevirumab-3) is a pan-lineage neutralizing human monoclonal antibody cocktail (8.9F, 12.1F, 37.D). Arevirumab protects cynomolgus monkeys from severe Lassa fever caused by lineage II and III LASV isolates. Arevirumab is applicable to research related to Lassa fever .

Cat. No.	Product Name

HY-L073

Anti-Hepatitis C Virus Compound Library	391 compounds
Hepatitis C virus (HCV) is a hepatotropic enveloped positive- strand RNA virus (family Flaviviridae) that infects the parenchymal cells of the liver. HCV infection is a significant public health burden. Globally, an estimated 71 million people have chronic hepatitis C virus infection. A significant number of those who are chronically infected will develop cirrhosis or liver cancer. To date, there is no vaccine against HCV, and combination pegylated alpha interferon (pIFN-) and ribavirin, the main standard-of-care treatment for HCV, is effective in only a subset of patients and is associated with a wide spectrum of toxic side effects and complications. More recently, new therapeutic approaches that target essential components of the HCV life cycle have been developed, including direct-acting antiviral (DAA) that specifically block a viral enzyme or functional protein and host-targeted agents (HTA) that block interactions between host proteins and viral components that are essential to the viral life cycle. However, the genetic diversity of HCV viruses and the stage of liver disease (i.e., cirrhosis) are revealing themselves as obstacles for effective, pan-genotypic treatments. There still exists a need for the discovery and development of new HCV inhibitors. In particular, since the future of HCV therapy will likely consist of a cocktail approach using multiple inhibitors that target different steps of infection, new antivirals targeting all steps of the viral infection cycle. MCE offers a unique collection of 391 compounds with identified and potential anti-HCV activity. MCE Anti- Hepatitis C Virus Compound Library is a useful tool for discovery new anti-HCV drugs and other anti-infection research.

Anti-Hepatitis C Virus Compound Library

391 compounds

Hepatitis C virus (HCV) is a hepatotropic enveloped positive- strand RNA virus (family Flaviviridae) that infects the parenchymal cells of the liver. HCV infection is a significant public health burden. Globally, an estimated 71 million people have chronic hepatitis C virus infection. A significant number of those who are chronically infected will develop cirrhosis or liver cancer. To date, there is no vaccine against HCV, and combination pegylated alpha interferon (pIFN-) and ribavirin, the main standard-of-care treatment for HCV, is effective in only a subset of patients and is associated with a wide spectrum of toxic side effects and complications. More recently, new therapeutic approaches that target essential components of the HCV life cycle have been developed, including direct-acting antiviral (DAA) that specifically block a viral enzyme or functional protein and host-targeted agents (HTA) that block interactions between host proteins and viral components that are essential to the viral life cycle. However, the genetic diversity of HCV viruses and the stage of liver disease (i.e., cirrhosis) are revealing themselves as obstacles for effective, pan-genotypic treatments. There still exists a need for the discovery and development of new HCV inhibitors. In particular, since the future of HCV therapy will likely consist of a cocktail approach using multiple inhibitors that target different steps of infection, new antivirals targeting all steps of the viral infection cycle.

MCE offers a unique collection of 391 compounds with identified and potential anti-HCV activity. MCE Anti- Hepatitis C Virus Compound Library is a useful tool for discovery new anti-HCV drugs and other anti-infection research.

Cat. No.	Product Name

HY-K0030

*Deacetylase Inhibitor Cocktail* (100× in 70% DMSO)**
MCE Deacetylase Inhibitor Cocktail is a synergistic combination of chemicals designed to preserve the acetylation state of proteins.The 1 mL volume is defined as the base specification. All larger sizes correspond to incremental volumes of this base.

HY-K1043

CEPT Cocktail 4 Publications Verification
MCE CEPT Cocktail is composed of CET small molecules (Chroman 1, Emricasan and Trans-ISRIB) and Polyamine Solution, and can effectively enhance cell survival and promote clonal growth of genetically stable hPSCs.

HY-K0011

*Protease Inhibitor Cocktail, mini-Tablet (EDTA-Free)* 250+ Cited Publications
MCE Protease Inhibitor Cocktail, mini-Tablet (EDTA-Free) is a blend of 5 pan-protease inhibitors for protection of protein integrity. The 25 pcs is defined as the base specification. All larger sizes correspond to incremental volumes of this base.

HY-K0023

*Phosphatase Inhibitor Cocktail* Ⅲ (100× in DMSO)** 240+ Cited Publications
Phosphatase Inhibitor Cocktail Ⅲ (100× in DMSO) is a mixture of multiple phosphatase inhibitors that effectively inhibit serine/threonine phosphatases and alkaline phosphatases, and is used to preserve the phosphorylation status of proteins.The 1 mL volume is defined as the base specification. All larger sizes correspond to incremental volumes of this base.

HY-K0022

*Phosphatase Inhibitor Cocktail* Ⅱ (100× in ddH₂O)** 455+ Cited Publications
Phosphatase Inhibitor Cocktail Ⅱ (100× in ddH₂O) is a blend of 5 phosphatase inhibitors that can broadly inhibit acid phosphatases, alkaline phosphatases, and protein tyrosine phosphatases (PTPs).The 1 mL volume is defined as the base specification. All larger sizes correspond to incremental volumes of this base.

HY-K0013

*Protease and Phosphatase Inhibitor Cocktail* (EDTA-Free, 10× in ddH₂O)** 140+ Cited Publications
MCE Protease and Phosphatase Inhibitor Cocktail (EDTA-Free, 10× in ddH₂O) protects protein from degradation by endogenous proteases released during protein extraction and purification.The 1 mL volume is defined as the base specification. All larger sizes correspond to incremental volumes of this base.

HY-K0021

*Phosphatase Inhibitor Cocktail* I (100× in DMSO)** 670+ Cited Publications
Phosphatase Inhibitor Cocktail I (100× in DMSO) is a blend of 2 phosphatase inhibitors that can effectively inhibit alkaline phosphatases and serine/threonine phosphatases. It is used to maintain the phosphorylation status of proteins.The 1 mL volume is defined as the base specification. All larger sizes correspond to incremental volumes of this base.

HY-K0010

*Protease Inhibitor Cocktail* (EDTA-Free, 100× in DMSO)** Maximum Cited Publications 1922 Publications Verification
MCE Protease Inhibitor Cocktail (EDTA-Free, 100× in DMSO) is a blend of 6 pan-protease inhibitors for protection of protein integrity.The 1 mL volume is defined as the base specification. All larger sizes correspond to incremental volumes of this base.

HY-K0012

*Protease Inhibitor Cocktail, Bacteria (EDTA-Free, 100× in DMSO)* 10+ Cited Publications
MCE Protease Inhibitor Cocktail, Bacteria (EDTA-Free, 100× in DMSO) protects proteins from degradation by endogenous proteases released during protein extraction and purification.The 1 mL volume is defined as the base specification. All larger sizes correspond to incremental volumes of this base.

HY-K0017

Kinase Inhibitor Cocktail 2 Publications Verification
MCE Kinase Inhibitor Cocktail controls the biological activity of kinases. This inhibitor is primarily used for Biochemicals applications.The 1 mL volume is defined as the base specification. All larger sizes correspond to incremental volumes of this base.

HY-K6021

*CEPT Cocktail* Plus (1000×)**
MCE CEPT Cocktail Plus (1000×) is a composite supplement specifically formulated for pluripotent stem cell culture. Through synergistic effects, it inhibits oxidative damage, blocks apoptotic pathways, and regulates protein translation, significantly reducing cellular stress levels through multiple targets. This dramatically improves the survival rate and cloning efficiency of pluripotent stem cells.

CEPT Cocktail Plus (1000×)

MCE CEPT Cocktail Plus (1000×) is a composite supplement specifically formulated for pluripotent stem cell culture. Through synergistic effects, it inhibits oxidative damage, blocks apoptotic pathways, and regulates protein translation, significantly reducing cellular stress levels through multiple targets. This dramatically improves the survival rate and cloning efficiency of pluripotent stem cells.

Cat. No.	Product Name	Target	Research Area	Image

HY-P99811

Rafivirumab CR57	RABV	Infection
Rafivirumab (CR57) is an anti-rabies virus monoclonal antibody for the prophylaxis of rabies. Rafivirumab has neutralizing potency against a broad spectrum of RABV variants. Rafivirumab can be used for research of cocktails .

HY-P992155

Arevirumab Arevirumab-3	Arenavirus	Infection
Arevirumab (Arevirumab-3) is a pan-lineage neutralizing human monoclonal antibody cocktail (8.9F, 12.1F, 37.D). Arevirumab protects cynomolgus monkeys from severe Lassa fever caused by lineage II and III LASV isolates. Arevirumab is applicable to research related to Lassa fever .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

MedchemExpress Validation 03

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred

MedchemExpress Validation 04

MedchemExpress Validation

We use cookies

MedChemExpress values your privacy and your trust is important to us. We use cookies to enhance your website experience. Some cookies are necessary to run the website. Privacy and Cookie Policy

Name
Email *

	Sorry, but the email address you supplied was invalid.